References
- Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010;9:520-32
- Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
- Ahlgren C, Oden A, Lycke J. High nationwide prevalence of multiple sclerosis in Sweden. Mult Scler 2011;17:901-8
- Richards RG, Sampson FC, Beard SM, et al. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002;6:1-73
- Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007;10:54-60
- Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med 1997;29:101-6
- Buchanan R, Huang C. Health-related quality of life among informal caregivers assisting people with multiple sclerosis. Disabil Rehabil 2011;33:113-21
- Dunn J. Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res 2010;10:433-40
- Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77:918-26
- Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ 2006;7(2 Suppl):S96-104
- Lobentanz IS, Asenbaum S, Vass K, et al. Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality. Acta Neurol Scand 2004;110:6-13
- Henriksson F, Fredrikson S, Masterman T, et al. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 2001;8:27-35
- Berg J, Lindgren P, Fredrikson S, et al. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ 2006;7(2 Suppl):S75-85
- Clar C, Velasco Garrido M, Gericke C, et al. Interferons and natalizumab for multiple sclerosis. GMS Health Technol Assess 2008;4:Doc09
- Oturai AB, Koch-Henriksen N, Petersen T, et al. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol 2009;16:420-3
- Rice GP, Incorvaia B, Munari L, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2001;preprint(4):CD002002
- FDA. Fingolimod (Gilenya) Prescribing and Labeling Information: latest label approved on 20/07/2011. 2011 http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022527s002lbl.pdf. [Last accessed March 8, 2012]
- EMA. Gilenya summary of product characteristics. 2012 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf. [Last accessed August 20, 2012]
- Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
- Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
- TLV. Price database of reimbursed drugs. 2012. http://www.tlv.se/beslut/sok/lakemedel. [Last accessed April 4, 2012]
- Holmen C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler 2011;17:708-19
- O'Day K, Meyer K, Miller RM, et al. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ 2011;14:617-27
- Nixon R, Eckert B, Cutter G, et al., editors. Indirect comparisons of oral fingolimod versus natalizumab and cladribine for the treatment of relapsing-remitting multiple sclerosis based on data from FREEDOMS, AFFIRM and CLARITY. ENS: 22nd meeting of the European Neurological Society 2012; Prague, Czech Republic, 9–12 June 2012
- EMA. Assessment report Gilenya (fingolimod). 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002202/WC500104529.pdf. [Last accessed March 8, 2012]
- General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). TLV; 2003. http://www.tlv.se/Upload/English/ENG-lfnar-2003-2.pdf. [Last accessed July 19, 2012]
- The Pharmaceutical Benefits Board. EMA. Tysabri summary of product characteristics. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000603/WC500044686.pdf. [Last accessed March 8, 2012]
- Swedish MS Society. Gilenya guidelines. 2011 . http://mssallskapet.se/SMSSrekGilenya.pdf. [Last accessed December 10, 2012]
- Swedish MS Society. Tysabri guidelines. 2011 . http://mssallskapet.se/rektysabri.pdf. [Last accessed December 10, 2012]
- EMA. Questions and answers on the review of Gilenya: outcome of a procedure under Article 20 of Regulation (EC) No 726/2004. 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2012/04/WC500125689.pdf. [Last accessed December 10, 2012]
- Gold R, Kappos L, Palace J, et al., editors. Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multi-centre FIRST study in relapsing multiple sclerosis patients. ENS: 22nd meeting of the European Neurology Society; 2012; Prague, Czech Republic, 9–12 June 2012
- Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics 2008;26:617-27
- Grytten Torkildsen N, Lie SA, Aarseth JH, et al. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Mult Scler 2008;14:1191-8
- Statistics Sweden. Life tables for Swedish population. 2004--2008. http://www.scb.se/Pages/ProductTables____25795.aspx. [Last accessed April 10, 2011]
- Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
- TLV. Decision on Tysabri. 2012. www.tlv.se/Upload/Beslut_2006/BES_061222_tysabri.pdf. [Last accessed April 4, 2012]
- DiMarco JP, O’Connor P, Cohen JA, et al., editors. First-dose effect of fingolimod: pooled safety data from two phase 3 studies (TRANSFORMS and FREEDOMS). ECTRIMS: 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2010; Gothenburg, Sweden